<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>13(9)</volume><submitter>Sun S</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Improving the efficacy of anti-programmed death 1 (PD-1) monoclonal antibody (mAb) therapy remains a major challenge for cancer immunotherapy in non-small cell lung cancer (NSCLC). Gut microbial metabolites can influence immunotherapy efficacy.&lt;h4>Methods&lt;/h4>ELISA was used to compare the serum 5-hydroxyindoleacetic acid (5-HIAA) level in patients with NSCLC. Humanized mice were constructed to observe the effect of 5-HIAA on immunotherapy. RNA-seq and flow cytometry were used to analyze the effect of 5-HIAA on tumor-infiltrating lymphocytes. The effects of phenelzine (Phe) and &lt;i>Akkermansia muciniphila&lt;/i> (&lt;i>AKK&lt;/i>) on 5-HIAA synthesis, antitumor immunity and immunotherapy efficacy were analyzed. Finally, the synergistic effect of Phe combined with &lt;i>AKK&lt;/i> on anti</pubmed_abstract><journal>Journal for immunotherapy of cancer</journal><pagination>e011831</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12421609</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Enhancing immunotherapy efficacy in NSCLC through the combined use of phenelzine and &amp;lt;i&amp;gt;Akkermansia muciniphila&amp;lt;/i&amp;gt; to regulate gut microbial metabolite 5-HIAA.</pubmed_title><pmcid>PMC12421609</pmcid><pubmed_authors>Zheng Y</pubmed_authors><pubmed_authors>Cui K</pubmed_authors><pubmed_authors>Li C</pubmed_authors><pubmed_authors>Chao K</pubmed_authors><pubmed_authors>Yu P</pubmed_authors><pubmed_authors>Wei Y</pubmed_authors><pubmed_authors>Li L</pubmed_authors><pubmed_authors>Wang L</pubmed_authors><pubmed_authors>Ding Y</pubmed_authors><pubmed_authors>Shen Z</pubmed_authors><pubmed_authors>Yang Y</pubmed_authors><pubmed_authors>Ji W</pubmed_authors><pubmed_authors>Zhu L</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Ge Y</pubmed_authors><pubmed_authors>Sun S</pubmed_authors><pubmed_authors>Sethi G</pubmed_authors><pubmed_authors>Zhao J</pubmed_authors><pubmed_authors>Song Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Enhancing immunotherapy efficacy in NSCLC through the combined use of phenelzine and &amp;lt;i&amp;gt;Akkermansia muciniphila&amp;lt;/i&amp;gt; to regulate gut microbial metabolite 5-HIAA.</name><description>&lt;h4>Background&lt;/h4>Improving the efficacy of anti-programmed death 1 (PD-1) monoclonal antibody (mAb) therapy remains a major challenge for cancer immunotherapy in non-small cell lung cancer (NSCLC). Gut microbial metabolites can influence immunotherapy efficacy.&lt;h4>Methods&lt;/h4>ELISA was used to compare the serum 5-hydroxyindoleacetic acid (5-HIAA) level in patients with NSCLC. Humanized mice were constructed to observe the effect of 5-HIAA on immunotherapy. RNA-seq and flow cytometry were used to analyze the effect of 5-HIAA on tumor-infiltrating lymphocytes. The effects of phenelzine (Phe) and &lt;i>Akkermansia muciniphila&lt;/i> (&lt;i>AKK&lt;/i>) on 5-HIAA synthesis, antitumor immunity and immunotherapy efficacy were analyzed. Finally, the synergistic effect of Phe combined with &lt;i>AKK&lt;/i> on anti</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Sep</publication><modification>2026-06-02T20:24:05.396Z</modification><creation>2026-04-20T03:09:58.743Z</creation></dates><accession>S-EPMC12421609</accession><cross_references><pubmed>40930748</pubmed><doi>10.1136/jitc-2025-011831</doi></cross_references></HashMap>